These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 12809878)

  • 1. Estimated economic costs of overactive bladder in the United States.
    Hu TW; Wagner TH; Bentkover JD; LeBlanc K; Piancentini A; Stewart WF; Corey R; Zhou SZ; Hunt TL
    Urology; 2003 Jun; 61(6):1123-8. PubMed ID: 12809878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related consequences of overactive bladder.
    Wagner TH; Hu TW; Bentkover J; LeBlanc K; Stewart W; Corey R; Zhou Z; Hunt T
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S598-607. PubMed ID: 12516954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of urinary incontinence and overactive bladder in the United States: a comparative study.
    Hu TW; Wagner TH; Bentkover JD; Leblanc K; Zhou SZ; Hunt T
    Urology; 2004 Mar; 63(3):461-5. PubMed ID: 15028438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of urgency urinary incontinence in the United States: a systematic review.
    Coyne KS; Wein A; Nicholson S; Kvasz M; Chen CI; Milsom I
    J Manag Care Pharm; 2014 Feb; 20(2):130-40. PubMed ID: 24456314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic impact of overactive bladder syndrome in six Western countries.
    Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C
    BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic impact of overactive bladder symptoms in Japan].
    Inoue S; Kobayashi M; Sugaya K
    Nihon Hinyokika Gakkai Zasshi; 2008 Nov; 99(7):713-22. PubMed ID: 19068687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The total economic burden of overactive bladder in the United States: a disease-specific approach.
    Onukwugha E; Zuckerman IH; McNally D; Coyne KS; Vats V; Mullins CD
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S90-7. PubMed ID: 19355803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining overactive bladder: epidemiology and burden of disease.
    Tubaro A
    Urology; 2004 Dec; 64(6 Suppl 1):2-6. PubMed ID: 15621220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and burden of overactive bladder in the United States.
    Stewart WF; Van Rooyen JB; Cundiff GW; Abrams P; Herzog AR; Corey R; Hunt TL; Wein AJ
    World J Urol; 2003 May; 20(6):327-36. PubMed ID: 12811491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related consequences of overactive bladder: an economic perspective.
    Hu TW; Wagner TH
    BJU Int; 2005 Sep; 96 Suppl 1():43-5. PubMed ID: 16086679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
    Qin L; Luo X; Zou KH; Snedecor SJ
    J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic costs of overactive bladder in the United States.
    Ganz ML; Smalarz AM; Krupski TL; Anger JT; Hu JC; Wittrup-Jensen KU; Pashos CL
    Urology; 2010 Mar; 75(3):526-32, 532.e1-18. PubMed ID: 20035977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overactive bladder patients and role of the pharmacist.
    Stewart K; McGhan WF; Offerdahl T; Corey R
    J Am Pharm Assoc (Wash); 2002; 42(3):469-76; quiz 477-8. PubMed ID: 12030634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey.
    Coyne KS; Payne C; Bhattacharyya SK; Revicki DA; Thompson C; Corey R; Hunt TL
    Value Health; 2004; 7(4):455-63. PubMed ID: 15449637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current and future burden and cost of overactive bladder in five European countries.
    Reeves P; Irwin D; Kelleher C; Milsom I; Kopp Z; Calvert N; Lloyd A
    Eur Urol; 2006 Nov; 50(5):1050-7. PubMed ID: 16753252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annual direct cost of urinary incontinence.
    Wilson L; Brown JS; Shin GP; Luc KO; Subak LL
    Obstet Gynecol; 2001 Sep; 98(3):398-406. PubMed ID: 11530119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic burden of overactive bladder in the United States: A systematic literature review.
    Powell LC; Szabo SM; Walker D; Gooch K
    Neurourol Urodyn; 2018 Apr; 37(4):1241-1249. PubMed ID: 29331047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder.
    Ricci JA; Baggish JS; Hunt TL; Stewart WF; Wein A; Herzog AR; Diokno AC
    Clin Ther; 2001 Aug; 23(8):1245-59. PubMed ID: 11558861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries.
    Sura S; Shiozawa A; Ng D; Aparasu RR
    J Am Med Dir Assoc; 2021 Jun; 22(6):1300-1306. PubMed ID: 33071158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic costs of overactive bladder in Germany.
    Klotz T; Brüggenjürgen B; Burkart M; Resch A
    Eur Urol; 2007 Jun; 51(6):1654-62; discussion 1662-3. PubMed ID: 17161521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.